Costs of multiple sclerosis therapy, from the perspective of patients and public payer depending on the stage of the disease Review article

Abstract

Prevalence, disability progression, the peak of morbidity at the age of the greatest productivity, the negative impact on the quality of life of patients and their families, long-term course of the disease indicate that multiple sclerosis is now an important health, social and economic problem. Aim of this study is to estimate the direct and indirect costs of treatment of multiple sclerosis on the basis of a survey. From the perspective of the patient attempted to estimate the cost: direct medical, non-medical, indirect, from the perspective of the payer’s – medical direct costs. The conclusions of the study are consistent with the trends observed in the Polish and foreign publications. Multiple sclerosis burden the budget of the patient, his family and public the payer significantly. The higher degree of severity of the disease, the higher direct and indirect costs.